Zurcher Kantonalbank Zurich Cantonalbank Purchases 5,064 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in NeoGenomics, Inc. (NASDAQ:NEO) by 19.7% during the 4th quarter, HoldingsChannel reports. The firm owned 30,707 shares of the medical research company’s stock after buying an additional 5,064 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in NeoGenomics were worth $497,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in NEO. BluePath Capital Management LLC bought a new position in shares of NeoGenomics in the third quarter worth $30,000. WINTON GROUP Ltd purchased a new position in NeoGenomics in the third quarter worth $133,000. Corton Capital Inc. purchased a new position in NeoGenomics in the third quarter worth $141,000. Aigen Investment Management LP purchased a new position in NeoGenomics in the third quarter worth $163,000. Finally, Mackenzie Financial Corp purchased a new position in NeoGenomics in the third quarter worth $199,000. Institutional investors own 98.50% of the company’s stock.

Insider Buying and Selling

In related news, General Counsel Alicia C. Olivo sold 2,587 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.96, for a total value of $38,701.52. Following the completion of the transaction, the general counsel now directly owns 34,866 shares of the company’s stock, valued at $521,595.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

NEO has been the subject of several research reports. The Goldman Sachs Group upped their target price on shares of NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. William Blair reiterated an “outperform” rating on shares of NeoGenomics in a research report on Wednesday, February 21st. Benchmark restated a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a research report on Wednesday. TD Cowen dropped their target price on shares of NeoGenomics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Needham & Company LLC dropped their target price on shares of NeoGenomics from $24.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, NeoGenomics currently has an average rating of “Moderate Buy” and a consensus price target of $19.78.

NeoGenomics Price Performance

NEO stock opened at $14.72 on Friday. NeoGenomics, Inc. has a 1 year low of $11.03 and a 1 year high of $21.22. The company has a market cap of $1.88 billion, a P/E ratio of -22.30 and a beta of 1.12. The firm has a 50-day moving average of $14.95 and a 200 day moving average of $15.95. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.48 and a quick ratio of 5.95.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. NeoGenomics had a negative net margin of 13.79% and a negative return on equity of 3.54%. The company had revenue of $155.55 million during the quarter, compared to the consensus estimate of $152.90 million. On average, sell-side analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.